iBio Inc. Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

12 Months Ended

Jun. 30, 2021

The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):


	Years ended
	June 30,
	2021		2020
Basic and diluted numerator:

Net loss attributable to iBio, Inc.	$	(23,207)	$	(16,439)
Deemed dividends – down round of Series A Preferred and Series B Preferred		—		(21,560)
Preferred stock dividends – iBio CMO Preferred Tracking Stock		(260)		(261)
Net loss available to iBio, Inc. stockholders	$	(23,467)	$	(38,260)

Basic and diluted denominator:

Weighted-average common shares outstanding		195,620		62,795

Per share amount	$	(0.12)	$	(0.61)

As of June 30, 2021, and 2020, shares issuable which could potentially dilute future earnings included were as follows.


	June 30,
	2021	2020
	(in thousands)
Stock options	8,542	3,476
Series A Preferred	—	—
Series B Preferred	—	28,925
Restricted stock units	674	41
Shares excluded from the calculation of diluted loss per share	9,216	32,442